5.80
前日終値:
$6.00
開ける:
$6.07
24時間の取引高:
24,652
Relative Volume:
0.59
時価総額:
$23.59M
収益:
-
当期純損益:
$-14.56M
株価収益率:
-0.3448
EPS:
-16.82
ネットキャッシュフロー:
$-12.46M
1週間 パフォーマンス:
-10.63%
1か月 パフォーマンス:
-3.97%
6か月 パフォーマンス:
+73.65%
1年 パフォーマンス:
+51.83%
Tenax Therapeutics Inc Stock (TENX) Company Profile
名前
Tenax Therapeutics Inc
セクター
電話
919-855-2100
住所
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
TENX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
TENX
Tenax Therapeutics Inc
|
5.80 | 23.59M | 0 | -14.56M | -12.46M | -16.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-24 | 開始されました | Leerink Partners | Outperform |
2024-10-14 | 開始されました | Guggenheim | Buy |
2024-09-30 | 開始されました | William Blair | Outperform |
2017-05-18 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
2014-12-16 | 開始されました | MLV & Co | Buy |
2014-11-18 | 開始されました | WallachBeth | Buy |
すべてを表示
Tenax Therapeutics Inc (TENX) 最新ニュース
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Exclusive: Tenax Leadership Team to Unveil Latest Phase 3 Progress at Major Healthcare Conference - Stock Titan
What is Leerink Partnrs’ Forecast for TENX Q1 Earnings? - Defense World
Equities Analysts Offer Predictions for TENX Q1 Earnings - Defense World
Q1 Earnings Estimate for TENX Issued By William Blair - Defense World
Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Research Analysts Set Expectations for TENX Q1 Earnings - Defense World
When (TENX) Moves Investors should Listen - news.stocktradersdaily.com
Tenax Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenax Therapeutics: Q4 Earnings Snapshot - CT Insider
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bluefield Daily Telegraph
Tenax Raises Massive $125M War Chest: Phase 3 Heart Failure Drug Trial Gets Major Boost - Stock Titan
Tenax Therapeutics Inc expected to post a loss of 42 cents a shareEarnings Preview - TradingView
Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com - Defense World
Tenax Therapeutics (TENX) to Release Earnings on Thursday - Defense World
Plastic Fencing Market to be Driven by Growing Residential and Commercial Construction Activities, Exclusive Research by The Insight Partners - GlobeNewswire Inc.
Tenax Therapeutics (NASDAQ:TENX) Given “Outperform” Rating at William Blair - Defense World
Promising Developments and Financial Backing Drive Buy Rating for Tenax Therapeutics - TipRanks
What is Roth Capital’s Estimate for TENX FY2024 Earnings? - Defense World
Roth Capital Predicts Weaker Earnings for Tenax Therapeutics - Defense World
(TENX) Proactive Strategies - news.stocktradersdaily.com
Tenax Therapeutics Announces $25 Million Private Placement - GlobeNewswire
Tenax Therapeutics announces $25M private placement - MSN
Tenax Therapeutics prices 378,346 shares at $6.04 in private placement - TipRanks
Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103 - TipRanks
Tenax Therapeutics secures $25 million in private placement - Investing.com India
Tenax Therapeutics Announces $25 Million Private Placement -March 05, 2025 at 08:54 am EST - Marketscreener.com
Tenax Therapeutics secures $25 million in private placement By Investing.com - Investing.com UK
Tenax Therapeutics Secures $25 Million From RTW Investments For Phase 3 Clinical Trials - StockTitan
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF - Yahoo Finance
Bristol Myers’ MyoKardia unit ends work with Fulcrum; ALX discloses layoffs - Endpoints News
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
Can Tenax Therapeutics' Conference Appearance Signal New Cardiovascular Treatment Progress? - StockTitan
Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017 - ACCESS Newswire
Tenax Therapeutics appoints new VP of Clinical Operations - MSN
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving Average – What’s Next? - Defense World
How the (TENX) price action is used to our Advantage - Stock Traders Daily
Leerink Partnrs Weighs in on TENX FY2029 Earnings - Defense World
David Risinger Recommends Buy for Tenax Therapeutics Amid Promising Phase 3 Trials and Growth Potential - TipRanks
Tenax Therapeutics (NASDAQ:TENX) Share Price Passes Above 200-Day Moving Average – What’s Next? - Defense World
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Exclusive: Tenax CEO to Reveal Latest Cardiovascular Drug Pipeline Updates at Major Biotech Conference - StockTitan
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations - The Manila Times
Tenax Therapeutics Inc (TENX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):